Lifecore director granted 25,907 RSUs

Lifecore Biomedical director Matthew E. Korenberg received a grant of 25,907 shares of common stock in the form of restricted stock units, with no cash paid per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Lifecore Biomedical director Matthew E. Korenberg received a grant of 25,907 shares of common stock in the form of restricted stock units, with no cash paid per share. This award is compensation, not an open-market purchase, and increases his direct holdings to 69,967 shares.

The restricted stock units convert into common stock on a 1-for-1 basis and vest on the earlier of June 4, 2027 or the date of the Lifecore Biomedical annual stockholders meeting first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026.

Insider Trade Summary

Grant/Award: 25,907 shares

Grant/Award 1 txn

Insider Korenberg Matthew E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,907	$0.00	$0.00

Holdings After Transaction: Common Stock — 69,967 shares (Direct)

Footnotes (2)

F1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Key Figures

RSU grant size: 25,907 shares Post-award holdings: 69,967 shares Grant price per share: $0.00 per share +2 more

5 metrics

RSU grant size 25,907 shares Restricted stock unit award to director Matthew E. Korenberg

Post-award holdings 69,967 shares Total Lifecore common shares held directly after the grant

Grant price per share $0.00 per share Reported price for the RSU award in the Form 4

RSU conversion ratio 1-for-1 Each RSU converts into one share of common stock

Latest vesting date June 4, 2027 Latest possible vesting trigger for the RSU award

Key Terms

restricted stock units, 1 for 1 basis, vests, annual meeting of stockholders

4 terms

restricted stock units financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

1 for 1 basis financial

"The restricted stock units convert into common stock ... on a 1 for 1 basis."

vests financial

"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders"

annual meeting of stockholders financial

"the date of the annual meeting of stockholders of the Company first held in calendar year 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lifecore Biomedical (LFCR) report for Matthew E. Korenberg?

Lifecore Biomedical reported that director Matthew E. Korenberg received 25,907 restricted stock units as a stock award. These RSUs convert into common shares on a 1-for-1 basis and are compensation, not an open-market stock purchase.

How many Lifecore Biomedical (LFCR) shares does Matthew E. Korenberg hold after this Form 4?

After this award, Matthew E. Korenberg directly holds 69,967 shares of Lifecore Biomedical common stock. The increase reflects the 25,907-share restricted stock unit grant reported in the Form 4 insider filing.

What are the vesting terms of Matthew E. Korenberg’s RSUs at Lifecore Biomedical (LFCR)?

Korenberg’s restricted stock units vest on the earlier of June 4, 2027, or the first annual stockholders meeting in calendar year 2027. That meeting must be held at least 50 weeks after June 4, 2026 for the vesting trigger to apply.

Did Matthew E. Korenberg buy Lifecore Biomedical (LFCR) shares on the open market?

No, the filing shows a stock award, not an open-market purchase. The 25,907 shares are restricted stock units granted as compensation, with a reported price per share of $0.00 in the Form 4 data.

What does the 1-for-1 conversion of RSUs mean for Lifecore Biomedical (LFCR)?

The 1-for-1 conversion means each restricted stock unit will become one share of Lifecore Biomedical common stock upon vesting. This ties the value of the award directly to future common share value at the time of vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/05/2026 - 04:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Korenberg Matthew E

(Last)

(First)

(Middle)

C/O LIFECORE BIOMEDICAL, INC.

3515 LYMAN BLVD.

(Street)

CHASKA

MINNESOTA

55318

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/04/2026		A		25,907	A	⁽¹⁾⁽²⁾	69,967	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Remarks:

	/s/ Courtney Schuler, Attorney-In-Fact for Matthew Korenberg	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR